A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study

• Published in: Medical journal. Armed Forces India Vol. 74; no. 2; pp. 148 - 153
• Main Authors: Rana, Vandana, Ranjan, Praveer, Jagani, Rajat, Rathi, K.R., Kumar, Dharmesh, Khera, Anurag
• Format: Journal Article
• Language: English
• Published: India Elsevier B.V 01.04.2018; Elsevier
• Subjects: ALK fusion oncogene; EGFR mutation; Indian; Lung adenocarcinoma; ORIGINAL ARTICLE; Targeted therapy; EGFR mutation; Indian; ALK fusion oncogene; Lung adenocarcinoma; Targeted therapy
• ISSN: 0377-1237
• DOI: 10.1016/j.mjafi.2017.09.005

Established predictive biomarkers for Non-Small Cell Lung Carcinoma (NSCLC) include sensitizing Epidermal Growth Factor Receptor (EGFR) mutations and Anaplastic Lymphoma Kinase (ALK) fusion oncogene. The primary aim of the study is to ascertain the prevalence of EGFR mutation and ALK gene rearrangement in patients of lung adenocarcinoma in Indian population and the second objective is to impress upon the importance of adequate processing of limited tissue samples. Histopathologically confirmed cases of lung adenocarcinoma, whose tumour had been tested for both EGFR and ALK gene mutations, were included in this study. The EGFR mutations were analyzed using PCR and Gene Sequencing. ALK fusion oncogene was found by Fluorescence In Situ Hybridization (FISH) technique using kit of Vysis LSI ALK Dual colour Break Apart Rearrangement probe. A total of 152 cases of lung adenocarcinoma were included. Out of which, 92 (60.5%) were male and 60 (39.5%) were female. After exclusion of 17 cases due to unsatisfactory result, EGFR mutations were found positive in 35.5% cases (48/135). ALK gene rearrangement was found in 7.6% (10/131) after excluding 21 cases with unsatisfactory result. EGFR mutations and ALK gene rearrangement was found to be mutually exclusive. Incidence of EGFR mutations (35.5%) is much higher in Indian population than in Caucasians (13%) and is close to the incidence in East Asian countries. The 7.6% incidence of ALK fusion oncogene in Indian patients establishes the importance of molecular studies to give maximum benefit of targeted therapy to the patients.